<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20450">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840669</url>
  </required_header>
  <id_info>
    <org_study_id>CM-FA-101</org_study_id>
    <nct_id>NCT02840669</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)</brief_title>
  <official_title>A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adverum Biotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Annapurna Therapeutics SAS, a wholly owned subsidiary of Adverum Biotechnologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Adverum Biotechnologies, Inc.</source>
  <brief_summary>
    <textblock>
      Friedreich's ataxia (FA) is an autosomal recessive disease with an incidence of 1/50,000 in
      the Caucasian population. The main manifestations of FA are progressive sensory and
      cerebellar ataxia and cardiomyopathy (CM). It is the most common form of inherited ataxia. A
      severe CM affects ~60% of FA patients, mostly young adults, and leads to cardiac failure
      then death. Currently, no therapy can change the course of this severe cardiomyopathy.

      This study is designed to characterize the cardiac manifestations of FA using cardiac
      magnetic resonance (CMR), echocardiography, serum cardiac biomarkers and evaluation of
      fatigue severity, in the context of the neurological disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise-stress test</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac magnetic resonance imaging (CMR)</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiogram</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of cardiac biomarkers in serum</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Friedreich's Ataxia</condition>
  <arm_group>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers (Controls)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac magnetic resonance imaging (CMR)</intervention_name>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <arm_group_label>Healthy Volunteers (Controls)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Exercise-stress test</intervention_name>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <arm_group_label>Healthy Volunteers (Controls)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiography (ECHO)</intervention_name>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <arm_group_label>Healthy Volunteers (Controls)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac-related blood studies</intervention_name>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <arm_group_label>Healthy Volunteers (Controls)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Friedreich's Ataxia):

          -  Males and females;

          -  ≥ 18 years old;

          -  Willing and able to provide informed consent;

          -  Definitive diagnosis of FA, based on clinical phenotype and genotype;

          -  With a hypertrophic cardiomyopathy;

          -  Ability to complete study assessments.

        Exclusion Criteria (Friedreich's Ataxia):

          -  Symptoms of cardiac failure;

          -  Moderate to severe atrial or ventricular arrhythmias;

          -  History of angina pectoris;

          -  Inability to undergo cardiac MRI;

          -  Clinical history or evidence of diabetes;

          -  Abnormal kidney function;

          -  Females who are pregnant or nursing;

          -  Receipt of an investigational drug within 30 days or 5 half-lives, or active
             enrollment in an investigational medication or device study;

          -  Inability to sit with back support;

          -  Inability to undergo exercise test;

          -  Inability to comply with all study requirements;

          -  Unaffiliated to any French health insurance or equivalent.

        Inclusion Criteria (Healthy Volunteers):

          -  Healthy males and females;

          -  ≥ 18 years old;

          -  Willing and able to provide informed consent;

          -  Age and gender matched to the Friedreich's Ataxia group;

          -  Ability to complete study assessments.

        Exclusion Criteria (Healthy Volunteers):

          -  Inability to undergo cardiac MRI;

          -  Clinical history or evidence of diabetes;

          -  Abnormal kidney function;

          -  Females who are pregnant or nursing;

          -  Receipt of an investigational drug within 30 days or 5 half-lives, or active
             enrollment in an investigational medication or device study;

          -  Inability to undergo exercise test;

          -  Inability to comply with all study requirements;

          -  Unaffiliated to any French health insurance or equivalent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Durr, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Pitié-Salpêtrière, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla Fiankan</last_name>
    <phone>+1 (650) 665-7025</phone>
    <email>cfiankan@adverum.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière, AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Durr</last_name>
    </contact>
    <investigator>
      <last_name>Alexandra Durr, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise Pousset, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alban Redheuil, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane Hatem, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 2, 2016</lastchanged_date>
  <firstreceived_date>July 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
